Current Headlines

1. Grace Therapeutics Announces Submission Of New Drug Application To U.S. Food And Drug Administration For GTx-104 6/25/2025

   Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced the submission to the U.S. Food and Drug Administration (FDA) of the Company’s New Drug Application (NDA) for GTx-104.

2. Scientists Find New Way To Predict How Bowel Cancer Drugs Will Stop Working 6/25/2025

   Scientists have developed a tool that can predict how bowel cancer adapts to treatment - helping researchers to design new personalised drugs that will keep patients living well for longer.

3. Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements With Cambrex And Thermo Fisher Scientific For Drug Substance And Drug Product Supply 6/25/2025

   Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD) in the US.

4. CARsgen Therapeutics Announces NDA Acceptance Of Satri-cel By China's NMPA 6/25/2025

   CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy.

5. Riliprubart Earns Orphan Drug Designation In The US For Antibody-Mediated Rejection In Solid Organ Transplantation 6/25/2025

   The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

6. A Glowing Biosensor For High-Throughput Drug Screening 6/24/2025

   Drug discovery can be a long and complex process. Medicines for neurodegenerative diseases like Alzheimer’s Disease are among the most expensive to develop, as animal model results have not proven to be predictive of efficacy in humans. Scientists usually have to screen many biological targets before identifying a single potential new drug.

7. Causaly Launches AI-Powered Competitive Intelligence Application For Research Scientists 6/24/2025

   Causaly today announced Pipeline Graph, giving life sciences research and development teams a more effective and efficient way to do competitive intelligence earlier in drug discovery.

8. Enhanced Genomics And The ALBORADA Drug Discovery Institute Partner To Accelerate Alzheimer's Drug Discovery 6/24/2025

   Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.

9. Axcelead DDP And Superluminal Announce The Intent To Collaborate On Drug Discovery Targeting Specific Molecular Mechanisms, Continuing A Productive Relationship 6/23/2025

   Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets.

10. XtalPi Announces Strategic Collaboration With Harvard Professor Gregory Verdine's DoveTree LLC To Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform 6/23/2025

    XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine.